List of Excipients in Branded Drug COMBIVIR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	COMBIVIR	lamivudine and zidovudine	21695-846	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	COMBIVIR	lamivudine and zidovudine	21695-846	COLLOIDAL SILICON DIOXIDE
Rebel Distributors Corp	COMBIVIR	lamivudine and zidovudine	21695-846	HYPROMELLOSES

Combivir Excipient Strategy and Commercial Opportunities

Last updated: October 17, 2026

Combivir is a fixed-dose antiretroviral tablet containing lamivudine 150 mg and zidovudine 300 mg. Its active-ingredient patents and FDA exclusivities have expired, shifting commercial value from molecule protection to low-cost manufacturing, bioequivalence, global procurement, pediatric adaptation, heat-stable supply, and differentiated excipient platforms. The principal formulation opportunity is a robust immediate-release tablet that matches the reference product’s dissolution and impurity profile while reducing coating, compression, and packaging costs.

What is Combivir and how is it formulated?

Combivir is an oral, film-coated tablet approved by the U.S. Food and Drug Administration in 1997 under NDA 020813. Glaxo Wellcome originally commercialized the product; the HIV business later became part of ViiV Healthcare. Each tablet contains:

Component	Amount per tablet	Function
Lamivudine	150 mg	Nucleoside reverse transcriptase inhibitor
Zidovudine	300 mg	Nucleoside reverse transcriptase inhibitor
Microcrystalline cellulose	Not publicly quantified	Diluent and compression aid
Sodium starch glycolate	Not publicly quantified	Disintegrant
Magnesium stearate	Not publicly quantified	Lubricant
Colloidal silicon dioxide	Not publicly quantified	Glidant
Hypromellose	Not publicly quantified	Film-forming coating polymer
Polyethylene glycol	Not publicly quantified	Plasticizer in the coating
Titanium dioxide	Not publicly quantified	Opacifier and colorant

The inactive-ingredient composition is reported in the FDA labeling and DailyMed product information.[1,2] The formulation is a conventional immediate-release compressed tablet rather than a modified-release or drug-delivery system.

What technical constraints govern the formulation?

The principal formulation constraints are:

1. Lamivudine and zidovudine must dissolve rapidly and consistently from the same tablet.
2. The product must maintain chemical stability under tropical and subtropical storage conditions.
3. The high total active load, 450 mg per tablet, leaves limited room for excipients.
4. Zidovudine has a recognized impurity and degradation burden that makes moisture, heat, and oxygen control relevant.
5. The formulation must support high-throughput compression without capping, lamination, sticking, or weight variation.
6. The tablet must remain acceptable for long-term adherence, including swallowability and coating integrity.

The reference product’s excipient system is conservative and widely available. That reduces technical barriers to generic development but also limits the scope for meaningful product differentiation.

What excipient strategy is appropriate for Combivir generics?

A commercial generic developer should prioritize a robust, low-cost, immediate-release platform over a novel excipient system. The preferred design is a direct-compression or dry-granulation process using compendial excipients with established regulatory histories.

Direct compression strategy

A direct-compression formulation may use:

• Microcrystalline cellulose for bulk and compactibility.
• Lactose monohydrate or anhydrous dibasic calcium phosphate as an alternative diluent.
• Crospovidone or croscarmellose sodium as alternative superdisintegrants.
• Colloidal silicon dioxide for flow improvement.
• Magnesium stearate or sodium stearyl fumarate for lubrication.
• Hypromellose-based film coating with polyethylene glycol or an equivalent plasticizer.

The principal advantage is a short manufacturing process with low water exposure. That matters for zidovudine stability and for plants operating in humid climates.

Dry granulation strategy

Roller compaction can improve flow and content uniformity when the formulation has poor powder handling characteristics. It also avoids aqueous processing. The tradeoff is increased process complexity and potential loss of compactability after milling.

Dry granulation is attractive where:

• The active blend segregates because of particle-size or density differences.
• The tablet press requires more consistent flow.
• Moisture exposure must be minimized.
• The manufacturer already operates roller-compaction equipment.

Wet granulation strategy

Aqueous wet granulation is technically possible but less attractive unless development data show a clear dissolution or compression benefit. It introduces additional drying, moisture exposure, and process-control requirements. Organic-solvent processing is commercially difficult because it increases environmental, safety, and regulatory burdens.

What excipients create commercial differentiation?

The strongest excipient opportunities are not new chemical entities. They are platform improvements that lower total cost or improve performance.

Opportunity	Potential benefit	Commercial value
Co-processed cellulose-silica excipient	Better flow and compactability	Lower compression failure and simpler blending
Crospovidone or croscarmellose substitution	Faster disintegration across hardness range	More robust dissolution control
Sodium stearyl fumarate	Lower hydrophobicity than magnesium stearate in some systems	Reduced risk of dissolution slowdown
Moisture-barrier film coating	Better stability in hot and humid markets	Lower degradation and longer shelf-life potential
Low-cost aqueous film coating	Reduced solvent and operating costs	More scalable global production
Smaller tablet architecture	Better swallowability	Improved adherence and pediatric or elderly usability
Lactose-free formulation	Broader excipient acceptability	Differentiation for selected markets
Titanium-dioxide-free coating	Regulatory and market-access flexibility	Simplified regional registration in jurisdictions with restrictions

Any excipient substitution must be evaluated against the reference product’s dissolution profile, impurity profile, assay, content uniformity, hardness, friability, disintegration, and stability. A formulation that is technically superior but produces materially different dissolution behavior may create additional bioequivalence risk.

What formulation patents protect Combivir?

The original Combivir formulation and combination-product protection have largely expired. The commercially relevant protection was historically concentrated in:

• The lamivudine and zidovudine active-ingredient patent families.
• Combination-use and fixed-dose product claims.
• Manufacturing and formulation claims associated with the branded product.
• Regulatory exclusivity linked to the original FDA approval.

The active-ingredient and combination-product estate is no longer a meaningful barrier to ordinary U.S. generic entry. FDA Orange Book records should be used for the live listing status of any specific patent number or product presentation.[3]

No current commercial strategy should assume that a new excipient combination automatically creates enforceable product exclusivity. A patentable formulation would need a defensible technical effect, such as improved stability, a narrower impurity profile, a materially improved dissolution window, or a clinically relevant tablet-size or adherence benefit. Routine substitution of microcrystalline cellulose, disintegrants, lubricants, or coating polymers is unlikely to provide strong exclusionary value by itself.

What manufacturing and intellectual-property barriers remain?

The meaningful barriers are operational rather than molecule-based:

• Demonstrating bioequivalence for a high-dose fixed combination.
• Controlling zidovudine-related degradation products.
• Maintaining content uniformity across a large batch.
• Establishing stability in Zone IVb conditions.
• Achieving acceptable dissolution after accelerated aging.
• Securing reliable API and excipient supply.
• Meeting WHO, FDA, and local pharmacopoeial requirements.
• Preserving low cost at public-sector tender volumes.

A formulation patent covering a specific excipient ratio, manufacturing sequence, or stabilization system may have value in selected markets, but it would need to survive obviousness challenges and demonstrate a measurable technical advantage.

When does Combivir lose exclusivity?

Combivir’s U.S. regulatory and patent exclusivity has expired. FDA approval occurred in 1997, and the product is now in the mature generic market.[1,3]

Milestone	Date or status
FDA approval of Combivir	September 26, 1997
Dosage form	Immediate-release film-coated tablet
Active ingredients	Lamivudine 150 mg and zidovudine 300 mg
New-chemical-entity exclusivity	Expired
Original combination-product exclusivity	Expired
U.S. generic pathway	Abbreviated New Drug Application
Current commercial position	Mature generic and public-health market

The exact patent expiration dates for historical patent families depend on the patent, terminal disclaimers, pediatric extensions, and jurisdiction. They do not create a current broad barrier to generic manufacture of the standard lamivudine/zidovudine tablet.

What is the Orange Book status of Combivir?

The Orange Book identifies FDA-approved drug products, therapeutic-equivalence information, patents, and exclusivity where applicable. Combivir is an approved prescription product, but its practical Orange Book significance is now limited because generic competition has eroded the original exclusivity position.[3]

For a proposed generic, the applicant would generally evaluate:

• Paragraph III certification if a listed patent remains unexpired.
• Paragraph IV certification if the applicant challenges an unexpired listed patent.
• Paragraph I or II certifications where applicable.
• Therapeutic-equivalence designation after approval.
• Product-specific labeling and bioequivalence requirements.

Because the principal commercial protection has expired, a new Paragraph IV strategy would have limited value unless a currently listed, enforceable formulation or method-of-use patent remains relevant to the proposed product.

Which companies are challenging Combivir exclusivity?

The market is no longer defined by a small number of branded challengers. Generic manufacturers, contract manufacturers, and public-health suppliers have supplied lamivudine/zidovudine combinations in multiple jurisdictions.

The competitive set includes:

• Large generic pharmaceutical companies.
• Indian and South African antiretroviral manufacturers.
• WHO-prequalified suppliers.
• Regional manufacturers serving government tenders.
• Private-label and contract-manufacturing organizations.

Competition is primarily price-based. A manufacturer with a reliable API source, WHO or stringent-regulatory-authority approval, and efficient packaging can compete without owning a differentiated patent estate.

What Paragraph IV challenges and litigation affect Combivir?

The historical litigation relevance of Combivir is limited compared with newer antiretroviral products. The product’s principal patents have aged out, and current market access does not depend on defeating a central, high-value patent barrier.

A Paragraph IV filing would be commercially relevant only if:

1. The Orange Book contained an unexpired patent covering the proposed product or use.
2. The patent had sufficient remaining term to justify litigation.
3. The applicant could support a credible non-infringement or invalidity position.
4. The expected market value exceeded legal and launch-at-risk costs.

For a mature fixed-dose tablet, the more likely legal issues are manufacturing quality, trademark, labeling, procurement qualification, and local registration rather than U.S. patent litigation.

What FDA regulatory status applies to Combivir generics?

A generic applicant would normally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The product must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

The development package typically includes:

• Same active ingredients, strengths, dosage form, and route.
• Comparative dissolution testing.
• In vivo bioequivalence where required.
• Stability data under ICH conditions.
• Impurity and degradation-product controls.
• Manufacturing-process validation.
• Container-closure qualification.
• Labeling consistent with the reference product.

The combination tablet does not normally require a new clinical-efficacy program when the applicant establishes the required pharmaceutical and bioequivalence standards.

What commercial opportunities exist for Combivir excipients?

Public-health and tender markets

The largest opportunity is low-cost supply for HIV treatment programs, particularly where fixed-dose combinations simplify procurement and adherence. Buyers often prioritize:

• WHO prequalification.
• Long shelf life.
• Zone IVb stability.
• Competitive tender pricing.
• Reliable supply continuity.
• Blister or bottle configurations suited to national programs.

An excipient strategy that reduces rejected batches, coating time, or stability failures can produce more value than a premium formulation claim.

Geographic expansion

The most attractive regions are markets with substantial public-sector HIV treatment programs and a preference for fixed-dose combinations. A manufacturer can use the same core tablet while adapting:

• Packaging language.
• Blister materials.
• Serialization.
• Local labeling.
• Child-resistant packaging.
• Stability commitments.
• Registration documentation.

A formulation with improved moisture protection can support distribution in hot and humid regions without requiring a more expensive cold-chain model.

Pediatric and adherence-oriented products

Combivir itself is a fixed adult-strength product. Commercial opportunities may exist in adjacent lamivudine/zidovudine products, including:

• Lower-strength pediatric tablets.
• Dispersible or mini-tablet formats.
• Oral powders or granules.
• Taste-masked dosage forms.
• Smaller adult tablets.
• Packaging aligned with adherence programs.

These products may require separate regulatory strategies and cannot be assumed to be covered by the original Combivir approval.

Excipient licensing

Excipient companies could license:

• Co-processed direct-compression systems.
• Moisture-protective coating platforms.
• Low-dose lubricant systems.
• Controlled-porosity disintegrant blends.
• Taste-masking systems for pediatric products.
• Ready-to-use coating systems for high-throughput plants.

The strongest licensing proposition would include comparative data against the reference formulation, accelerated stability data, dissolution robustness, and manufacturing-cost analysis.

How strong is the Combivir patent estate?

The current patent estate is weak as a barrier to standard generic entry because the product is mature and its core exclusivities have expired. Its remaining strategic value lies in:

• Historical know-how.
• Manufacturing experience.
• Regulatory precedent.
• Brand recognition in HIV treatment.
• Supply relationships.
• Public-sector procurement qualifications.

A new entrant should not rely on patent blocking. It should compete through cost, quality, supply continuity, geographic registrations, and differentiated dosage forms.

What generic launch scenarios exist?

Launch scenario	Product strategy	Expected competitive basis
Standard U.S. generic	Immediate-release tablet matching reference	Price and approval timing
WHO-prequalified product	Robust tablet with Zone IVb stability	Public-sector tenders
Low-cost emerging-market product	Direct compression and simplified packaging	Manufacturing economics
Premium stability product	Moisture-barrier coating and packaging	Longer shelf life and fewer failures
Pediatric extension	Lower-strength or dispersible dosage form	Adherence and age-specific dosing
Private-label supply	Contract-manufactured equivalent	Distribution reach and tender access
Excipient platform licensing	Co-processed or coating technology	Manufacturing performance

How does Combivir compare with newer antiretroviral combinations?

Combivir has a weaker commercial position than newer regimens because lamivudine and zidovudine are older agents, zidovudine has tolerability limitations, and treatment guidelines have moved toward regimens based on integrase inhibitors such as dolutegravir.[4]

Product attribute	Combivir	Newer integrase-inhibitor combinations
Core actives	Lamivudine and zidovudine	Often integrase inhibitor plus two NRTIs
Patent position	Mature and largely expired	Frequently stronger or more recently expired
Manufacturing complexity	Low to moderate	Moderate
Public-health relevance	Existing and selected markets	Broad first-line use in many guidelines
Price pressure	High	Variable
Excipient differentiation	Limited	More potential for stability and specialized dosage forms
Revenue outlook	Mature, declining, tender-driven	Higher where protected or guideline-preferred

What revenue exposure does the legacy product create?

Combivir revenue is exposed to:

• Generic price erosion.
• Substitution by newer antiretroviral regimens.
• Declining use of zidovudine-containing therapy.
• Public tender compression.
• Regional treatment-guideline changes.
• API and supply-chain volatility.
• Brand discontinuation or reduced commercial promotion.

For an excipient supplier, the addressable opportunity is therefore volume-driven rather than margin-driven. The best targets are generic manufacturers with multi-country registrations, not the legacy brand alone.

Key Takeaways

• Combivir contains lamivudine 150 mg and zidovudine 300 mg in an immediate-release film-coated tablet.
• The reference excipient system uses microcrystalline cellulose, sodium starch glycolate, magnesium stearate, colloidal silicon dioxide, hypromellose, polyethylene glycol, and titanium dioxide.
• Core patent and regulatory exclusivities have expired, leaving no strong molecule-level barrier to standard generic entry.
• Direct compression or dry granulation is generally the most commercially attractive manufacturing approach.
• The highest-value excipient opportunities involve moisture control, dissolution robustness, compression reliability, and pediatric adaptation.
• Public-health tenders, WHO-prequalified supply, and emerging-market registrations are more important than U.S. patent exclusivity.
• A new formulation patent requires a measurable technical effect; routine excipient substitution is unlikely to create durable protection.
• Newer integrase-inhibitor regimens limit long-term growth in zidovudine-containing products.

FAQs

Can lactose replace microcrystalline cellulose in a Combivir generic?

Yes, lactose may be evaluated as a diluent, but the substitution must be supported by comparative dissolution, content-uniformity, compression, impurity, and stability data.

Is a titanium-dioxide-free Combivir formulation commercially useful?

It can simplify regulatory positioning in markets with restrictions or heightened scrutiny of titanium dioxide, but it must preserve coating opacity, appearance, photoprotection, and stability.

Does Combivir require a novel excipient for generic approval?

No. Generic development normally relies on established compendial excipients and an ANDA-based demonstration of pharmaceutical equivalence and bioequivalence.

Can a smaller Combivir tablet support new patent protection?

A smaller tablet may support a formulation patent only if it produces a non-obvious technical result, such as materially improved swallowability, compression performance, dissolution, or stability.

Is a pediatric Combivir product covered by the adult tablet approval?

No. A pediatric strength, dispersible tablet, oral powder, or other dosage form generally requires its own regulatory submission and product-specific quality and bioequivalence justification.

References

1. U.S. Food and Drug Administration. (1997). Combivir (lamivudine and zidovudine) tablets, NDA 020813: Prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: Combivir, lamivudine and zidovudine tablet, film coated.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. World Health Organization. (2023). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach.